How to Get a Novocare® Wegovy® Coupon
Learn how to access a Novocare® Wegovy® coupon to help lower out-of-pocket costs. Discover how Eden helps you connect with licensed providers for care.
Learn how Novocare® may help patients with diabetes access valuable education, tools, and provider-connected support to better manage their care.
Managing diabetes is a long-term commitment, and for many individuals, the right educational and support tools may enhance their ability to stay engaged in care. Novocare, an initiative by Novo Nordisk, offers a suite of patient-focused resources that may support those living with type 2 diabetes. These tools include savings programs, educational guides, and condition management resources that are easy to access and simple to understand.
For patients exploring their treatment options, including FDA-approved GLP-1 medications for type 2 diabetes, platforms like Eden may help connect them with licensed healthcare providers from the comfort of their home.
Novocare® is a support platform developed by Novo Nordisk that offers educational and planning tools for individuals living with diabetes. It is especially useful for those managing type 2 diabetes and seeking reliable information about medication options, nutrition, and daily health routines.
Novocare® does not replace care from a licensed healthcare provider. Instead, it provides self-guided resources that may support patients as they work with their providers to manage their condition.
Novocare® includes a variety of educational materials, articles, videos, and printables that may help patients better understand how type 2 diabetes affects the body and what treatment options may be available. These materials are written in accessible language and organized by topic.
Novocare® provides information about savings programs for certain FDA-approved Novo Nordisk medications. These programs are subject to eligibility based on insurance status and other factors. Individuals can visit the official Novocare® website to learn more. Eden does not provide or manage these savings programs.
From meal planning templates to wellness goal sheets, Novocare® offers tools that may assist patients in creating healthy routines. These resources are designed to complement the care plan developed by a licensed healthcare provider.
{{primary-cta}}
Eden is a digital health platform that facilitates access to independent, licensed healthcare providers. Eden does not diagnose, treat, or prescribe medications. All medical evaluations, treatment decisions, and prescriptions are made solely by the providers patients connect with through the platform.
Through Eden, patients can access virtual appointments with licensed providers who may prescribe FDA-approved medications such as semaglutide when clinically appropriate. Providers on the Eden platform evaluate each individual's health profile and offer personalized treatment plans tailored to the patient's medical history and goals.
Patients can also:
GLP-1 receptor agonists, such as semaglutide, are FDA-approved for the treatment of type 2 diabetes. In certain formulations, GLP-1 medications are also approved for chronic weight management in adults with obesity or those who are overweight and have at least one weight-related condition, such as high blood pressure or type 2 diabetes.
These medications mimic a natural hormone involved in regulating blood sugar and appetite signals. Licensed healthcare providers may consider GLP-1 therapy as part of a personalized care plan when clinically appropriate. While peer-reviewed studies have examined potential outcomes in specific populations, treatment decisions must be made on an individual basis in consultation with a licensed provider.
For individuals managing type 2 diabetes, Novocare® offers supportive tools that may enhance their understanding and day-to-day care routine. These resources do not replace provider guidance but may serve as helpful supplements.
If you're looking for access to licensed healthcare providers to discuss type 2 diabetes treatments, Eden may help you take the next step. Through Eden, patients can schedule virtual visits with experienced providers who evaluate eligibility for treatments such as FDA-approved GLP-1 medications and offer personalized care plans.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Eden is not a medical provider or a pharmacy. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by independent, state-licensed pharmacies. Eden does not manufacture, own, or dispense any medications. Please consult a licensed healthcare provider before making any medical decisions.
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/s0140-6736(21)00213-0
Novo Nordisk. 2024. Diabetes Education Resources. Novocare. https://www.novocare.com/diabetes/education.html
Novo Nordisk. 2024. Savings Card Eligibility and Program Info. Novocare. https://www.novocare.com/eligibility/obesity-savings-card.html
Novo Nordisk. 2024. Meal Planning & Nutrition for Diabetes. Novocare.https://diabeteseducation.novocare.com/healthy-eating.html
Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183